Treatment of cryptosporidiosis

Cryptosporidium: Parasite and Disease

Volumn , Issue , 2014, Pages 455-486

  Mead, Jan R ^a   Arrowood, Michael J ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84946759584     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-7091-1562-6_11     Document Type: Chapter

References (175)

1. Abrahamsen MS, Templeton TJ, Enomoto S, Abrahante JE, Zhu G, Lancto CA, Deng M, Liu C, Widmer G, Tzipori S, Buck GA, Xu P, Bankier AT, Dear PH, Konfortov BA, Spriggs HF Iyer L, Anantharaman V, Aravind L, Kapur V (2004) Complete genome sequence of the apicomplexan, Cryptosporidium parvum. Science 304(5669):441-445
2. Abubakar I, Aliyu SH, Arumugam C, Hunter PR, Usman NK (2007) Prevention and treatment of cryptosporidiosis in immunocompromised patients. Cochrane Database Syst Rev (1): CD004932. doi:10.1002/14651858.CD004932.pub2
3. Amadi B, Mwiya M, Musuku J, Watuka A, Sianongo S, Ayoub A, Kelly P (2002) Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial. Lancet 360(9343):1375-1380
4. Armson A, Sargent K, MacDonald LM, Finn MP, Thompson RC, Reynoldson JA (1999) A comparison of the effects of two dinitroanilines against Cryptosporidium parvum in vitro and in vivo in neonatal mice and rats. FEMS Immunol Med Microbiol 26(2):109-113
5. Armson A, Menon K, O’Hara A, MacDonald LM, Read CM, Sargent K, Thompson RC Reynoldson JA (2002) Efficacy of oryzalin and associated histological changes in Cryptosporidium- infected neonatal rats. Parasitology 125(Pt 2):113-117
6. Arrowood MJ, Mead JR, Mahrt JL, Sterling CR (1989) Effects of immune colostrum and orally administered antisporozoite monoclonal antibodies on the outcome of Cryptosporidium parvum infections in neonatal mice. Infect Immun 57:2283-2288
7. Arrowood MJ, Mead JR, Xie L, You X (1996) In vitro anticryptosporidial activity of dinitroaniline herbicides. FEMS Microbiol Lett 136(3):245-249
8. Artz JD, Dunford JE, Arrowood MJ, Dong A, Chruszcz M, Kavanagh KL, Minor W, Russell RG Ebetino FH, Oppermann U, Hui R (2008) Targeting a uniquely nonspecific prenyl synthase with bisphosphonates to combat cryptosporidiosis. Chem Biol 15(12):1296-1306
9. Artz JD, Wernimont AK, Allali-Hassani A, Zhao Y, Amani M, Lin YH, Senisterra G, Wasney GA, Fedorov O, King O, Roos A, Lunin VV, Qiu W, Finerty P Jr, Hutchinson A, Chau I, von Delft F, MacKenzie F, Lew J, Kozieradzki I, Vedadi M, Schapira M, Zhang C, Shokat K Heightman T, Hui R (2011) The Cryptosporidium parvum kinome. BMC Genomics 12:478
10. Bacchi CJ, Narlett N (1995) Polyamine metabolism. In: Marr JJ, MullerM(eds) Biochemistry and molecular biology of parasites. Academic, New York, pp 119-131
11. Beckers CJ, Roos DS, Donald RG, Luft BJ, Schwab JC, Cao Y, Joiner KA (1995) Inhibition of cytoplasmic and organellar protein synthesis in Toxoplasma gondii. Implications for the target of macrolide antibiotics. J Clin Invest 95(1):367-376
12. Benbow JW, Bernberg EL, Korda A, Mead JR (1998) Synthesis and evaluation of dinitroanilines for treatment of cryptosporidiosis. Antimicrob Agents Chemother 42(2):339-343
13. Benitez AJ, McNair N, Mead J (2007) Modulation of gene expression of three Cryptosporidium parvum ATP-binding cassette transporters in response to drug treatment. Parasitol Res 101 (6):1611-1616
14. Benitez AJ, McNair N, Mead JR (2009) Oral immunization with attenuated Salmonella enterica serovar Typhimurium encoding Cryptosporidium parvum Cp23 and Cp40 antigens induces a specific immune response in mice. Clin Vaccine Immunol 16(9):1272-1278
15. Benitez A, Priest JW, Ehigiator HN, McNair N, Mead JR (2011) Evaluation of DNA encoding acidic ribosomal protein P2 of Cryptosporidium parvum as a potential vaccine candidate for cryptosporidiosis. Vaccine 29(49):9239-9245
16. Bessoff K, Sateriale A, Lee KK, Huston CD (2013) Drug repurposing screen reveals FDA-approved inhibitors of human HMG-CoA reductase and isoprenoid synthesis that block Cryptosporidium parvum growth. Antimicrob Agents Chemother 57(4):1804-1814
17. Blagburn BL, Soave R (1997) Prophylaxis and chemotherapy: human and animal. In: Fayer R (ed) Cryptosporidium and cryptosporidiosis. CRC Press, Boca Raton, pp 111-128
18. Blagburn BL, Drain KL, Land TM, Kinard RG, Moore PH, Lindsay DS, Patrick DA, Boykin DW Tidwell RR (1998) Comparative efficacy evaluation of dicationic carbazole compounds, nitazoxanide, and paromomycin against Cryptosporidium parvum infections in a neonatal mouse model. Antimicrob Agents Chemother 42(11):2877-2882
19. Blanshard C, Shanson DC, Gazzard BG (1997) Pilot studies of azithromycin, letrazuril and paromomycin in the treatment of cryptosporidiosis. Int J STD AIDS 8(2):124-129
20. Bobin S, Bouhour D, Durupt S, Boibieux A, Girault V, Peyramond D (1998) Importance of antiproteases in the treatment of microsporidia and/or cryptosporidia infections in HIV-seropositive patients. Pathol Biol 46(6):418-419
21. Bonafonte MT, Romagnoli PA, McNair N, Shaw AP, Scanlon M, Leitch GJ, Mead JR (2004) Cryptosporidium parvum: effect of multi-drug reversing agents on the expression and function of ATP-binding cassette transporters. Exp Parasitol 106(3-4):126-134
22. Boulter-Bitzer JI, Lee H, Trevors JT (2007) Molecular targets for detection and immunotherapy in Cryptosporidium parvum. Biotechnol Adv 25(1):13-44
23. Brophy VH, Vasquez J, Nelson RG, Forney JR, Rosowsky A, Sibley CH (2000) Identification of Cryptosporidium parvum dihydrofolate reductase inhibitors by complementation in Saccharomyces cerevisiae. Antimicrob Agents Chemother 44(4):1019-1028
24. Burton AJ, Nydam DV, Jones G, Zambriski JA, Linden TC, Cox G, Davis R, Brown A, Bowman DD (2011) Antibody responses following administration of a Cryptosporidium parvum rCP15/60 vaccine to pregnant cattle. Vet Parasitol 175(1-2):178-181
25. Carr A, Marriott D, Field A, Vasak E, Cooper DA (1998) Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy. Lancet 351 (9098):256-261
26. Carreno RA, Martin DS, Barta JR (1999) Cryptosporidium is more closely related to the gregarines than to coccidia as shown by phylogenetic analysis of apicomplexan parasites inferred using small-subunit ribosomal RNA gene sequences. Parasitol Res 85(11):899-904
27. Clastre M, Goubard A, Prel A, Mincheva Z, Viaud-Massuart MC, Bout D, Rideau M, Velge-Roussel F, Laurent F (2007) The methylerythritol phosphate pathway for isoprenoid biosynthesis in coccidia: presence and sensitivity to fosmidomycin. Exp Parasitol 116(4):375-384
28. Crabb JH (1998) Antibody-based immunotherapy of cryptosporidiosis. Adv Parasitol 40:121-149
29. Denkinger CM, Harigopal P, Ruiz P, Dowdy LM (2008) Cryptosporidium parvum-associated sclerosing cholangitis in a liver transplant patient. Transpl Infect Dis 10(2):133-136
30. Dillingham RA, Lima AA, Guerrant RL (2002) Cryptosporidiosis: epidemiology and impact. Microbes Infect 4(10):1059-1066
31. Dillingham RA, Pinkerton R, Leger P, Severe P, Guerrant RL, Pape JW, Fitzgerald DW (2009) High early mortality in patients with chronic acquired immunodeficiency syndrome diarrhea initiating antiretroviral therapy in Haiti: a case-control study. Am J Trop Med Hyg 80 (6):1060-1064
32. Doumbo O, Rossignol JF, Pichard E, Traore HA, Dembele TM, Diakite M, Traore F, Diallo DA (1997) Nitazoxanide in the treatment of cryptosporidial diarrhea and other intestinal parasitic infections associated with acquired immunodeficiency syndrome in tropical Africa. Am J Trop Med Hyg 56(6):637-639
33. Doyle PS, Crabb J, Petersen C (1993) Anti-Cryptosporidium parvum antibodies inhibit infectivity in vitro and in vivo. Infect Immun 61(10):4079-4084
34. Edlind T, Visvesvara G, Li J, Katiyar S (1994) Cryptosporidium and microsporidial beta-tubulin sequences: predictions of benzimidazole sensitivity and phylogeny. J Eukaryot Microbiol 41 (5):S 38
35. Ehigiator HN, Romagnoli P, Priest JW, Secor WE, Mead JR (2007) Induction of murine immune responses by DNA encoding a 23-kDa antigen of Cryptosporidium parvum. Parasitol Res 101 (4):943-950
36. Fan X, Upadhyaya B, Wu L, Koh C, Santin-Duran M, Pittaluga S, Uzel G, Kleiner D, Williams E, Ma CA, Bodansky A, Oliveira JB, Edmonds P, Hornung R, Wong DW, Fayer R, Fleisher T Heller T, Prussin C, Jain A (2012) CD40 agonist antibody mediated improvement of chronic Cryptosporidium infection in patients with X-linked hyper IgM syndrome. Clin Immunol 143 (2):152-161
37. Fayer R, Ellis W (1993a) Glycoside antibiotics alone and combined with tetracyclines for prophylaxis of experimental cryptosporidiosis in neonatal BALB/c mice. J Parasitol 79 (4):553-558
38. Fayer R, Ellis W (1993b) Paromomycin is effective as prophylaxis for cryptosporidiosis in dairy calves. J Parasitol 79(5):771-774
39. Fayer R, Fetterer R (1995) Activity of benzimidazoles against cryptosporidiosis in neonatal BALB/c mice. J Parasitol 81(5):794-795
40. Fayer R, Andrews C, Ungar BLP, Blagburn B (1989) Efficacy of hyperimmune bovine colostrum for prophylaxis of cryptosporidiosis in neonatal calves. J Parasitol 75:393-397
41. Fichera ME, Roos DS (1997) A plastid organelle as a drug target in apicomplexan parasites. Nature 390(6658):407-409
42. Fichtenbaum CJ, Zackin R, Feinberg J, Benson C, Griffiths JK, Team ACTGNWCS (2000) Rifabutin but not clarithromycin prevents cryptosporidiosis in persons with advanced HIV infection. AIDS 14(18):2889-2893
43. Flanigan TP, Soave R (1993) Cryptosporidiosis. [Review]. Prog Clin Parasitol 3:1-20
44. Floren CH, Chinenye S, Elfstrand L, Hagman C, Ihse I (2006) ColoPlus, a new product based on bovine colostrum, alleviates HIV-associated diarrhoea. Scand J Gastroenterol 41(6):682-686
45. Forney JR, DeWald DB, Yang S, Speer CA, Healey MC (1999) A role for host phosphoinositide 3- kinase and cytoskeletal remodeling during Cryptosporidium parvum infection. Infect Immun 67(2):844-852
46. Fries L, Hillman K, Crabb JH, Linberg S, Hamer D, Griffiths J, Keusch G, Soave R, Petersen C (1994) Clinical and microbiological effects of bovine anti-Cryptosporidium immunoglobulin (BACI) on cryptosporidial diarrhea in patients with AIDS. In: 34th interscience conference on antimicrobial agents and chemotherapy, Orlando. p Abstract 198
47. Fujikawa H, Miyakawa H, Iguchi K, Nishizawa M, Moro K, Nagai K, Ishibashi M (2002) Intestinal cryptosporidiosis as an initial manifestation in a previously healthy Japanese patient with AIDS. J Gastroenterol 37(10):840-843
48. Gargala G, Delaunay A, Li X, Brasseur P, Favennec L, Ballet JJ (2000) Efficacy of nitazoxanide, tizoxanide and tizoxanide glucuronide against Cryptosporidium parvum development in sporozoite-infected HCT-8 enterocytic cells. J Antimicrob Chemother 46(1):57-60
49. Gargala G, Le Goff L, Ballet JJ, Favennec L, Stachulski AV, Rossignol JF (2010) Evaluation of new thiazolide/thiadiazolide derivatives reveals nitro group-independent efficacy against in vitro development of Cryptosporidium parvum. Antimicrob Agents Chemother 54 (3):1315-1318
50. Gargala G, Francois A, Favennec L, Rossignol JF (2013) Activity of halogeno-thiazolides against Cryptosporidium parvum in experimentally- infected immunosuppressed gerbils (Meriones unguiculatus). Antimicrob Agents Chemother 57(6):2821-2823
51. Giacometti A, Cirioni O, Scalise G (1996) In-vitro activity of macrolides alone and in combination with artemisin, atovaquone, dapsone, minocycline or pyrimethamine against Cryptosporidium parvum. J Antimicrob Chemother 38(3):399-408
52. Giacometti A, Burzacchini F, Cirioni O, Barchiesi F, Dini M, Scalise G (1999) Efficacy of treatment with paromomycin, azithromycin, and nitazoxanide in a patient with disseminated cryptosporidiosis. Eur J Clin Microbiol Infect Dis 18(12):885-889
53. Giacometti A, Cirioni O, Barchiesi F, Ancarani F, Scalise G (2000) Activity of nitazoxanide alone and in combination with azithromycin and rifabutin against Cryptosporidium parvum in cell culture. J Antimicrob Chemother 45(4):453-456
54. Giacometti A, Cirioni O, Del Prete MS, Barchiesi F, Fineo A, Scalise G (2001) Activity of buforin II alone and in combination with azithromycin and minocycline against Cryptosporidium parvum in cell culture. J Antimicrob Chemother 47(1):97-99
55. Goldberg E, Bishara J (2012) Contemporary unconventional clinical use of co-trimoxazole. Clin Microbiol Infect 18(1):8-17
56. Gorla SK, Kavitha M, Zhang M, Liu X, Sharling L, Gollapalli DR, Striepen B, Hedstrom L, Cuny GD (2012) Selective and potent urea inhibitors of Cryptosporidium parvum inosine 50-monophosphate dehydrogenase. J Med Chem 55(17):7759-7771
57. Graczyk Z, Chomicz L, Kozlowska M, Kazimierczuk Z, Graczyk TK (2011) Novel and promising compounds to treat Cryptosporidium parvum infections. Parasitol Res 109(3):591-594
58. Greenberg PD, Cello JP (1996) Treatment of severe diarrhea caused by Cryptosporidium parvum with oral bovine immunoglobulin concentrate in patients with AIDS. J AIDS Hum Retrovirol 13(4):348-354
59. Griffiths JK, Balakrishnan R, Widmer G, Tzipori S (1998) Paromomycin and geneticin inhibit intracellular Cryptosporidium parvum without trafficking through the host cell cytoplasm: implications for drug delivery. Infect Immun 66(8):3874-3883
60. Harris M, Deutsch G, MacLean JD, Tsoukas CM (1994) A phase I study of letrazuril in AIDSrelated cryptosporidiosis. AIDS 8(8):1109-1113
61. He H, Zhao B, Liu L, Zhou K, Qin X, Zhang Q, Li X, Zheng C, Duan M (2004) The humoral and cellular immune responses in mice induced by DNA vaccine expressing the sporozoite surface protein of Cryptosporidium parvum. DNA Cell Biol 23(5):335-339
62. Healey MC, Yang S, Rasmussen KR, Jackson MK, Du C (1995) Therapeutic efficacy of paromomycin in immunosuppressed adult mice infected with Cryptosporidium parvum. J Parasitol 81(1):114-116
63. Hewitt RG, Yiannoutsos CT, Higgs ES, Carey JT, Geiseler PJ, Soave R, Rosenberg R, Vazquez GJ, Wheat LJ, Fass RJ, Antoninievic Z, Walawander AL, Flanigan TP, Bender JF (2000) Paromomycin: no more effective than placebo for treatment of cryptosporidiosis in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trial Group. Clin Infect Dis 31(4):1084-1092
64. Holmberg SD, Moorman AC, Von Bargen JC, Palella FJ, Loveless MO, Ward DJ, Navin TR (1998) Possible effectiveness of clarithromycin and rifabutin for cryptosporidiosis chemoprophylaxis in HIV disease. HIV Outpatient Study (HOPS) Investigators. J Am Med Assoc 279 (5):384-386
65. Hommer V, Eichholz J, Petry F (2003) Effect of antiretroviral protease inhibitors alone, and in combination with paromomycin, on the excystation, invasion and in vitro development of Cryptosporidium parvum. J Antimicrob Chemother 52(3):359-364
66. Hong-Xuan H, Lei C, Cheng-Min W, Kai Z, Yi T, Xi-Ming Q, Ming-Xing D (2005) Expression of the recombinant fusion protein CP15-23 of Cryptosporidium parvum and its protective test. J Nanosci Nanotechnol 5(8):1292-1296
67. Huston CD, Petri WA Jr (2001) Emerging and reemerging intestinal protozoa. Curr Opin Gastroenterol 17(1):17-23
68. Imboden M, Riggs MW, Schaefer DA, Homan EJ, Bremel RD (2010) Antibodies fused to innate immune molecules reduce initiation of Cryptosporidium parvum infection in mice. Antimicrob Agents Chemother 54(4):1385-1392
69. Ives NJ, Gazzard BG, Easterbrook PJ (2001) The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART) in a London clinic. J Infect 42 (2):134-139
70. Jenkins MC (2004) Present and future control of cryptosporidiosis in humans and animals. Expert Rev Vaccines 3(6):669-671
71. Jenkins M, Kerr D, Fayer R, Wall R (1995) Serum and colostrum antibody responses induced by jet-injection of sheep with DNA encoding a Cryptosporidium parvum antigen. Vaccine 13 (17):1658-1664
72. Jenkins MC, O’Brien C, Trout J, Guidry A, Fayer R (1999) Hyperimmune bovine colostrum specific for recombinant Cryptosporidium parvum antigen confers partial protection against cryptosporidiosis in immunosuppressed adult mice. Vaccine 17(19):2453-2460
73. Johnson EH, Windsor JJ, Muirhead DE, King GJ, Al-Busaidy R (2000) Confirmation of the prophylactic value of paromomycin in a natural outbreak of caprine cryptosporidiosis. Vet Res Commun 24(1):63-67
74. Johnson SM, Murphy RC, Geiger JA, DeRocher AE, Zhang Z, Ojo KK, Larson ET, Perera BG, Dale EJ, He P, Reid MC, Fox AM, Mueller NR, Merritt EA, Fan E, Parsons M, Van Voorhis WC, Maly DJ (2012) Development of Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) inhibitors with potent anti-toxoplasma activity. J Med Chem 55(5):2416-2426
75. Johnson CR, Gorla SK, Kavitha M, Zhang M, Liu X, Striepen B, Mead JR, Cuny GD, Hedstrom L (2013) Phthalazinone inhibitors of inosine-50-monophosphate dehydrogenase from Cryptosporidium parvum. Bioorg Med Chem Lett 23(4):1004-1007
76. Jordan WC (1996) Clarithromycin prophylaxis against Cryptosporidium enteritis in patients with AIDS. J Natl Med Assoc 88(7):425-427
77. Kadappu KK, Nagaraja MV, Rao PV, Shastry BA (2002) Azithromycin as treatment for cryptosporidiosis in human immunodeficiency virus disease. J Postgrad Med 48(3):179-181
78. Katiyar SK, Gordon VR, Mclaughlin GL, Edlind TD (1994) Antiprotozoal activities of benzimidazoles and correlations with beta-tubulin sequence. Antimicrob Agents Chemother 38(9):2086-2090
79. Keithly JS, Zhu G, Upton SJ, Woods KM, Martinez MP, Yarlett N (1997) Polyamine biosynthesis in Cryptosporidium parvum and its implications for chemotherapy. Mol Biochem Parasitol 88 (1-2):35-42
80. Kelly GS (2003) Bovine colostrums: a review of clinical uses. Altern Med Rev 8(4):378-394
81. Kimata I, Uni S, Iseki M (1991) Chemotherapeutic effect of azithromycin and lasalocid on Cryptosporidium infection in mice. J Protozool 38(6):S232-S233
82. Klein P, Cirioni O, Giacometti A, Scalise G (2008) In vitro and in vivo activity of aurintricarboxylic acid preparations against Cryptosporidium parvum. J Antimicrob Chemother 62 (5):1101-1104
83. Kotloff KL, Nataro JP, Blackwelder WC, Nasrin D, Farag TH, Panchalingam S, Wu Y, Sow SO, Sur D, Breiman RF, Faruque AS, Zaidi AK, Saha D, Alonso PL, Tamboura B, Sanogo D, Onwuchekwa U, Manna B, Ramamurthy T, Kanungo S, Ochieng JB, Omore R, Oundo JO, Hossain A, Das SK, Ahmed S, Qureshi S, Quadri F, Adegbola RA, Antonio M, Hossain MJ, Akinsola A, Mandomando I, Nhampossa T, Acacio S, Biswas K, O’Reilly CE, Mintz ED Berkeley LY, Muhsen K, Sommerfelt H, Robins-Browne RM, Levine MM (2013) Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet 382 (9888):209-222
84. Lawton P, Pelandakis M, Petavy AF, Walchshofer N (2007) Overexpression, purification and characterization of a hexahistidine-tagged recombinant extended nucleotide-binding domain 1 (NBD1) of the Cryptosporidium parvum CpABC3 for rational drug design. Mol Biochem Parasitol 152(1):101-107
85. Leander BS, Clopton RE, Keeling PJ (2003) Phylogeny of gregarines (Apicomplexa) as inferred from small-subunit rDNA and beta-tubulin. Int J Syst Evol Microbiol 53(1):345-354
86. Ling Y, Sahota G, Odeh S, Chan JM, Araujo FG, Moreno SN, Oldfield E (2005) Bisphosphonate inhibitors of Toxoplasma gondi growth: in vitro, QSAR, and in vivo investigations. J Med Chem 48(9):3130-3140
87. Lopez-Velez R, Tarazona R, Garcia Camacho A, Gomez-Mampaso E, Guerrero A, Moreira V Villanueva R (1995) Intestinal and extraintestinal cryptosporidiosis in AIDS patients. Eur J Clin Microbiol Infect Dis 14(8):677-681
88. Mancassola R, Reperant JM, Naciri M, Chartier C (1995) Chemoprophylaxis of Cryptosporidium parvum infection with paromomycin in kids and immunological study. Antimicrob Agents Chemother 39(1):75-78
89. Manque PA, Tenjo F, Woehlbier U, Lara AM, Serrano MG, Xu P, Alves JM, Smeltz RB, Conrad DH, Buck GA (2011) Identification and immunological characterization of three potential vaccinogens against Cryptosporidium species. Clin Vaccine Immunol 18(11):1796-1802
90. Martin MB, Grimley JS, Lewis JC, Heath HT III, Bailey BN, Kendrick H, Yardley V, Caldera A Lira R, Urbina JA, Moreno SN, Docampo R, Croft SL, Oldfield E (2001) Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapy. J Med Chem 44(6):909-916
91. Martucci WE, Udier-Blagovic M, Atreya C, Babatunde O, Vargo MA, Jorgensen WL, Anderson KS (2009) Novel non-active site inhibitor of Cryptosporidium hominis TS-DHFR identified by a virtual screen. Bioorg Med Chem Lett 19(2):418-423
92. Mather MW, Henry KW, Vaidya AB (2007) Mitochondrial drug targets in apicomplexan parasites. Curr Drug Targets 8(1):49-60
93. Mead J, McNair N (2006) Antiparasitic activity of flavonoids and isoflavones against Cryptosporidium parvum and Encephalitozoon intestinalis. FEMS Microbiol Lett 259(1):153-157
94. Mead JR, Benbow JW, Garmon D, Stewart J (1999) Improved efficacy of dinitroaniline analogs for use as anti-cryptosporidial drugs. J Eukaryot Microbiol 46(5):62S-63S
95. Mead JR, Fauq AH, Khan MA, McNair N (2003) Efficacy of glycoconjugated dinitroanilines against Cryptosporidium parvum. J Eukaryot Microbiol 50(Suppl):550-552
96. Mele R, Gomez Morales MA, Tosini F, Pozio E (2003) Indinavir reduces Cryptosporidium parvum infection in both in vitro and in vivo models. Int J Parasitol 33(7):757-764
97. Miao YM, Awad-El-Kariem FM, Franzen C, Ellis DS, Muller A, Counihan HM, Hayes PJ Gazzard BG (2000) Eradication of cryptosporidia and microsporidia following successful antiretroviral therapy. J AIDS 25(2):124-129
98. Mor SM, Tzipori S (2008) Cryptosporidiosis in children in Sub-Saharan Africa: a lingering challenge. Clin Infect Dis 47(7):915-921
99. Moreno B, Bailey BN, Luo S, Martin MB, Kuhlenschmidt M, Moreno SN, Docampo R, Oldfield E (2001) (31)P NMR of apicomplexans and the effects of risedronate on Cryptosporidium parvum growth. Biochem Biophys Res Commun 284(3):632-637
100. Müller J, Sidler D, Nachbur U, Wastling J, Brunner T, Hemphill A (2008) Thiazolides inhibit growth and induce glutathione-S-transferase Pi (GSTP1)-dependent cell death in human colon cancer cells. Int J Cancer 123(8):1797-1806
101. Murphy RC, Ojo KK, Larson ET, Castellanos-Gonzalez A, Perera BG, Keyloun KR, Kim JE, Bhandari JG, Muller NR, Verlinde CL, White AC Jr, Merritt EA, Van Voorhis WC, Maly DJ (2010) Discovery of potent and selective inhibitors of calcium-dependent protein kinase 1 (CDPK1) from C. parvum and T. gondii. ACS Med Chem Lett 1(7):331-335
102. Nelson RG, Rosowsky A (2001) Dicyclic and tricyclic diaminopyrimidine derivatives as potent inhibitors of Cryptosporidium parvum dihydrofolate reductase: structure-activity and structure-selectivity correlations. Antimicrob Agents Chemother 45(12):3293-3303
103. Nime FA, Burek JD, Page DL, Holscher MA, Yardley JH (1976) Acute enterocolitis in a human being infected with the protozoan Cryptosporidium. Gastroenterology 70(4):592-598
104. Nord J, Ma P, Dijohn D, Tzipori S, Tacket CO (1990) Treatment with bovine hyperimmune colostrum of cryptosporidial diarrhea in AIDS patients. AIDS 4(6):581-584
105. O’Neil RH, Lilien RH, Donald BR, Stroud RM, Anderson AC (2003) Phylogenetic classification of protozoa based on the structure of the linker domain in the bifunctional enzyme, dihydrofolate reductase-thymidylate synthase. J Biol Chem 278(52):52980-52987
106. Ojo KK, Larson ET, Keyloun KR, Castaneda LJ, Derocher AE, Inampudi KK, Kim JE, Arakaki TL, Murphy RC, Zhang L, Napuli AJ, Maly DJ, Verlinde CL, Buckner FS, Parsons M, Hol WG, Merritt EA, Van Voorhis WC (2010) Toxoplasma gondii calcium-dependent protein kinase 1 is a target for selective kinase inhibitors. Nat Struct Mol Biol 17(5):602-607
107. Okhuysen PC, Chappell CL, Crabb J, Valdez LM, Douglass ET, DuPont HL (1998) Prophylactic effect of bovine anti-Cryptosporidium hyperimmune colostrum immunoglobulin in healthy volunteers challenged with Cryptosporidium parvum. Clin Infect Dis 26(6):1324-1329
108. Ollivett TL, Nydam DV, Bowman DD, Zambriski JA, Bellosa ML, Linden TC, Divers TJ (2009) Effect of nitazoxanide on cryptosporidiosis in experimentally infected neonatal dairy calves. J Dairy Sci 92(4):1643-1648
109. Palmieri F, Cicalini S, Froio N, Rizzi EB, Goletti D, Festa A, Macri G, Petrosillo N (2005) Pulmonary cryptosporidiosis in an AIDS patient: successful treatment with paromomycin plus azithromycin. Int J STD AIDS 16(7):515-517
110. Pelphrey PM, Popov VM, Joska TM, Beierlein JM, Bolstad ES, Fillingham YA, Wright DL Anderson AC (2007) Highly efficient ligands for dihydrofolate reductase from Cryptosporidium hominis and Toxoplasma gondii inspired by structural analysis. J Med Chem 50 (5):940-950
111. Perkins ME, Riojas YA, Wu TW, Le Blancq SM (1999) CpABC, a Cryptosporidium parvum ATP-binding cassette protein at the host-parasite boundary in intracellular stages. Proc Natl Acad Sci U S A 96(10):5734-5739
112. Perryman LE, Bjorneby JM (1991) Immunotherapy of cryptosporidiosis in immunodeficient animal models. J Protozool 38(6):S98-S100
113. Perryman LE, Riggs MW, Mason PH, Fayer R (1990) Kinetics of Cryptosporidium parvum sporozoite neutralization by monoclonal antibodies, immune bovine serum, and immune bovine colostrum. Infect Immun 58:257-259
114. Perryman LE, Kapil SJ, Jones ML, Hunt EL (1999) Protection of calves against cryptosporidiosis with immune bovine colostrum induced by a Cryptosporidium parvum recombinant protein. Vaccine 17(17):2142-2149
115. Popov VM, Chan DC, Fillingham YA, Atom Yee W, Wright DL, Anderson AC (2006) Analysis of complexes of inhibitors with Cryptosporidium hominis DHFR leads to a new trimethoprim derivative. Bioorg Med Chem Lett 16(16):4366-4370
116. Popov VM, Yee WA, Anderson AC (2007) Towards in silico lead optimization: scores from ensembles of protein/ligand conformations reliably correlate with biological activity. Proteins 66(2):375-387
117. Portnoy D, Whiteside ME, Buckley E III, MacLeod CL (1984) Treatment of intestinal cryptosporidiosis with spiramycin. Ann Intern Med 101:202-204
118. Pozio E, Rivasi F, Caccio SM (2004) Infection with Cryptosporidium hominis and reinfection with Cryptosporidium parvum in a transplanted ileum. APMIS 112(4-5):309-313
119. Priest JW, Kwon JP, Montgomery JM, Bern C, Moss DM, Freeman AR, Jones CC, Arrowood MJ Won KY, Lammie PJ, Gilman RH, Mead JR (2010) Cloning and characterization of the acidic ribosomal protein P2 of Cryptosporidium parvum, a new 17-kilodalton antigen. Clin Vaccine Immunol 17(6):954-965
120. Rahman M, Chapel H, Chapman RW, Collier JD (2012) Cholangiocarcinoma complicating secondary sclerosing cholangitis from cryptosporidiosis in an adult patient with CD40 ligand deficiency: case report and review of the literature. Int Arch Allergy Immunol 159(2):204-208
121. Rehg JE (1991) Anti-cryptosporidial activity of macrolides in immunosuppressed rats. J Protozool 38(6):S228-S230
122. Riggs MW, Stone AL, Yount PA, Langer RC, Arrowood MJ, Bentley DL (1997) Protective monoclonal antibody defines a circumsporozoite-like glycoprotein exoantigen of Cryptosporidium parvum sporozoites and merozoites. J Immunol 158:1787-1795
123. Riordan CE, Langreth SG, Sanchez LB, Kayser O, Keithly JS (1999) Preliminary evidence for a mitochondrion in Cryptosporidium parvum: phylogenetic and therapeutic implications. J Eukaryot Microbiol 46(5):52S-55S
124. Roche JK, Rojo AL, Costa LB, Smeltz R, Manque P, Woehlbier U, Bartelt L, Galen J, Buck G Guerrant RL (2013) Intranasal vaccination in mice with an attenuated Salmonella enterica Serovar 908htr A expressing Cp15 of Cryptosporidium: impact of malnutrition with preservation of cytokine secretion. Vaccine 31(6):912-918
125. Rohlman VC, Kuhls TL, Mosier DA, Crawford DL, Hawkins DR, Abrams VL, Greenfield RA (1993) Therapy with atovaquone for Cryptosporidium parvum infection in neonatal severe combined immunodeficiency mice. J Infect Dis 168(1):258-260
126. Roos MH (1997) The role of drugs in the control of parasitic nematode infections: must we do without? Parasitology 114(7):S137-S144
127. Rossignol JF, Hidalgo H, Feregrino M, Higuera F, Gomez WH, Romero JL, Padierna J, Geyne A Ayers MS (1998) A double-‘blind’ placebo-controlled study of nitazoxanide in the treatment of cryptosporidial diarrhoea in AIDS patients in Mexico. Trans R Soc Trop Med Hyg 92 (6):663-666
128. Rossignol JF, Ayoub A, Ayers MS (2001) Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, double-blind, placebo-controlled study of nitazoxanide. J Infect Dis 184(1):103-106
129. Russell TS, Lynch J, Ottolini MG (1998) Eradication of Cryptosporidium in a child undergoing maintenance chemotherapy for leukemia using high dose azithromycin therapy. J Pediatr Hematol Oncol 20(1):83-85
130. Saez-Llorens X, Odio CM, Umana MA, Morales MV (1989) Spiramycin vs. placebo for treatment of acute diarrhea caused by Cryptosporidium. Pediatr Infect Dis J 8(3):136-140
131. Sagodira S, Buzoni-Gatel D, Iochmann S, Naciri M, Bout D (1999a) Protection of kids against Cryptosporidium parvum infection after immunization of dams with CP15-DNA. Vaccine 17 (19):2346-2355
132. Sagodira S, Iochmann S, Mevelec MN, Dimier-Poisson I, Bout D (1999b) Nasal immunization of mice with Cryptosporidium parvum DNA induces systemic and intestinal immune responses. Parasite Immunol 21(10):507-516
133. Sauvage V, Aubert D, Escotte-Binet S, Villena I (2009) The role of ATP-binding cassette (ABC) proteins in protozoan parasites. Mol Biochem Parasitol 167(2):81-94
134. Saxon A, Weinstein W (1987) Oral administration of bovine colostrum anti-cryptosporidia antibody fails to alter the course of human cryptosporidiosis. J Parasitol 73:413-415
135. Schaefer DA, Auerbach-Dixon BA, Riggs MW (2000) Characterization and formulation of multiple epitope-specific neutralizing monoclonal antibodies for passive immunization against cryptosporidiosis. Infect Immun 68(5):2608-2616
136. Seddon J, Bhagani S (2011) Antimicrobial therapy for the treatment of opportunistic infections in HIV/AIDS patients: a critical appraisal. HIV/AIDS 3:19-33
137. Sharling L, Liu X, Gollapalli DR, Maurya SK, Hedstrom L, Striepen B (2010) A screening pipeline for antiparasitic agents targeting Cryptosporidium inosine monophosphate dehydrogenase. PLoS Negl Trop Dis 4(8):e794
138. Smith NH, Cron S, Valdez LM, Chappell CL, White AC Jr (1998) Combination drug therapy for cryptosporidiosis in AIDS. J Infect Dis 178(3):900-903
139. Soave R, Dieterich D, Kotler D, Gassyuk E, Tierney AR, Liebes L (1990) Oral diclazuril therapy for cryptosporidiosis. Paper presented at the Sixth International Conference on AIDS, San Francisco, CA, June 20-23, 1990. [Note: published December 30, 1990]
140. Sodqi M, Marih L, Lahsen AO, Bensghir R, Chakib A, Himmich H, El Filali KM (2012) Causes of death among 91 HIV-infected adults in the era of potent antiretroviral therapy. Presse Med 41 (7-8):e386-e390
141. Sprinz E, Mallman R, Barcellos S, Silbert S, Schestatsky G, Bem David D (1998) AIDS-related cryptosporidial diarrhoea: an open study with roxithromycin. J Antimicrob Chemother 41 (Suppl B):85-91
142. Stachulski AV, Berry NG, Lilian Low AC, Moores SL, Row E, Warhurst DC, Adagu IS, Rossignol JF (2006) Identification of isoflavone derivatives as effective anticryptosporidial agents in vitro and in vivo. J Med Chem 49(4):1450-1454
143. Stefani HN, Levi GC, Amato Neto V, Braz LM, Azevedo HD, Possa TA, Silva NF, de Mendonca JS, Fernandes AO (1996) The treatment of cryptosporidiosis in AIDS patients using paromomycin. Rev Soc Bras Med Trop 29(4):355-357
144. Stokkermans TJ, Schwartzman JD, Keenan K, Morrissette NS, Tilney LG, Roos DS (1996) Inhibition of Toxoplasma gondii replication by dinitroaniline herbicides. Exp Parasitol 84 (3):355-370
145. Striepen B, White MW, Li C, Guerini MN, Malik SB, Logsdon JM Jr, Liu C, Abrahamsen MS (2002) Genetic complementation in apicomplexan parasites. Proc Natl Acad Sci U S A 99 (9):6304-6309
146. Strong WB, Nelson RG (2000) Preliminary profile of the Cryptosporidium parvum genome: an expressed sequence tag and genome survey sequence analysis. Mol Biochem Parasitol 107 (1):1-32
147. Sun XE, Sharling L, Muthalagi M, Mudeppa DG, Pankiewicz KW, Felczak K, Rathod PK, Mead J Striepen B, Hedstrom L (2010) Prodrug activation by Cryptosporidium thymidine kinase. J Biol Chem 285(21):15916-15922
148. Tali A, Addebbous A, Asmama S, Chabaa L, Zougaghi L (2011) Respiratory cryptosporidiosis in two patients with HIV infection in a tertiary care hospital in Morocco. Ann Biol Clin 69 (5):605-608
149. Templeton TJ, Enomoto S, Chen WJ, Huang CG, Lancto CA, Abrahamsen MS, Zhu G (2010) A genome-sequence survey for Ascogregarina taiwanensis supports evolutionary affiliation but metabolic diversity between a Gregarine and Cryptosporidium. Mol Biol Evol 27(2):235-248
150. Theodos CM, Griffiths JK, D’Onfro J, Fairfield A, Tzipori S (1998) Efficacy of nitazoxanide against Cryptosporidium parvum in cell culture and in animal models. Antimicrob Agents Chemother 42(8):1959-1965
151. Tilley M, Upton SJ, Fayer R, Barta JR, Chrisp CE, Freed PS, Blagburn BL, Anderson BC, Barnard SM (1991) Identification of a 15-kilodalton surface glycoprotein on sporozoites of Cryptosporidium parvum. Infect Immun 59(3):1002-1007
152. Traub-Cseko YM, Ramalho-Ortigao JM, Dantas AP, de Castro SL, Barbosa HS, Downing KH (2001) Dinitroaniline herbicides against protozoan parasites: the case of Trypanosoma cruzi. Trends Parasitol 17(3):136-141
153. Tzipori S, Roberton D, Chapman C (1986) Remission of diarrhoea due to cryptosporidiosis in an immunodeficient child treated with hyperimmune bovine colostrum. Br Med J 293:1276-1277
154. Tzipori S, Griffiths J, Theodus C (1995) Paromomycin treatment against cryptosporidiosis in patients with AIDS. J Infect Dis 171(4):1069-1070; author reply 1071
155. Uip DE, Lima AL, Amato VS, Boulos M, Neto VA, Bem David D (1998) Roxithromycin treatment for diarrhoea caused by Cryptosporidium spp. in patients with AIDS. J Antimicrob Chemother 41(Suppl B):93-97
156. Umejiego NN, Gollapalli D, Sharling L, Volftsun A, Lu J, Benjamin NN, Stroupe AH, Riera TV Striepen B, Hedstrom L (2008) Targeting a prokaryotic protein in a eukaryotic pathogen: identification of lead compounds against cryptosporidiosis. Chem Biol 15(1):70-77
157. Ungar BLP, Ward DJ, Fayer R, Quinn CA (1990) Cessation of Cryptosporidium-associated diarrhea in an acquired immunodeficiency syndrome patient after treatment with hyperimmune bovine colostrum. Gastroenterology 98:486-489
158. Vargas SL, Shenep JL, Flynn PM, Pui CH, Santana VM, Hughes WT (1993) Azithromycin for treatment of severe Cryptosporidium diarrhea in two children with cancer. J Pediatr 123 (1):154-156
159. Vasquez JR, Gooze L, Kim K, Gut J, Petersen C, Nelson RG (1996) Potential antifolate resistance determinants and genotypic variation in the bifunctional dihydrofolate reductase-thymidylate synthase gene from human and bovine isolates of Cryptosporidium parvum. Mol Biochem Parasitol 79(2):153-165
160. Verdier RI, Fitzgerald DW, Johnson WD Jr, Pape JW (2000) Trimethoprim-sulfamethoxazole compared with ciprofloxacin for treatment and prophylaxis of Isospora belli and Cyclospora cayetanensis infection in HIV-infected patients. A randomized, controlled trial. Ann Intern Med 132(11):885-888
161. Viu M, Quilez J, Sanchez-Acedo C, del Cacho E, Lopez-Bernad F (2000) Field trial on the therapeutic efficacy of paromomycin on natural Cryptosporidium parvum infections in lambs. Vet Parasitol 90(3):163-170
162. Wang C, Luo J, Amer S, Guo Y, Hu Y, Lu Y, Wang H, Duan M, He H (2010) Multivalent DNA vaccine induces protective immune responses and enhanced resistance against Cryptosporidium parvum infection. Vaccine 29(2):323-328
163. Weikel C, Lazenby A, Belitsos P, Mcdewitt M, Fleming HE, Barbacci M (1991) Intestinal injury associated with spiramycin therapy of Cryptosporidium infection in AIDS. J Protozool 38(6): S147
164. Wernimont AK, Artz JD, Finerty P Jr, Lin YH, Amani M, Allali-Hassani A, Senisterra G Vedadi M, Tempel W, Mackenzie F, Chau I, Lourido S, Sibley LD, Hui R (2010) Structures of apicomplexan calcium-dependent protein kinases reveal mechanism of activation by calcium. Nat Struct Mol Biol 17(5):596-601
165. White AC, Chappell CL, Hayat CS, Kimball KT, Flanigan TP, Goodgame RW (1994) Paromomycin for cryptosporidiosis in aids - a prospective, double-blind trial. J Infect Dis 170(2):419-424
166. Wilson RJ, Williamson DH (1997) Extrachromosomal DNA in the Apicomplexa. Microbiol Mol Biol Rev 61(1):1-16
167. Wittenberg DF, Miller NM, van den Ende J (1989) Spiramycin is not effective in treating Cryptosporidium diarrhea in infants: results of a double-blind randomized trial. J Infect Dis 159:131-132
168. Woods KM, Nesterenko MV, Upton SJ (1996) Efficacy of 101 antimicrobials and other agents on the development of Cryptosporidium parvum in vitro. Ann Trop Med Parasitol 90(6):603-615
169. You X, Schinazi RF, Arrowood MJ, Lejkowski M, Juodawlkis AS, Mead JR (1998) In-vitro activities of paromomycin and lasalocid evaluated in combination against Cryptosporidium parvum. J Antimicrob Chemother 41(2):293-296
170. Zapata F, Perkins ME, Riojas YA, Wu TW, Le Blancq SM (2002) The Cryptosporidium parvum ABC protein family. Mol Biochem Parasitol 120(1):157-161
171. Zhang Z, Ojo KK, Johnson SM, Larson ET, He P, Geiger JA, Castellanos-Gonzalez A, White AC Jr, Parsons M, Merritt EA, Maly DJ, Verlinde CL, Van Voorhis WC, Fan E (2012) Benzoylbenzimidazole-based selective inhibitors targeting Cryptosporidium parvum and Toxoplasma gondii calcium-dependent protein kinase-1. Bioorg Med Chem Lett 22 (16):5264-5267
172. Zhu G, Keithly JS, Philippe H (2000a) What is the phylogenetic position of Cryptosporidium? Int J Syst Evol Microbiol 50(Pt 4):1673-1681
173. Zhu G, Marchewka MJ, Keithly JS (2000b) Cryptosporidium parvum appears to lack a plastid genome. Microbiology 146(2):315-321
174. Zhu G, Marchewka MJ, Woods KM, Upton SJ, Keithly JS (2000c) Molecular analysis of a Type I fatty acid synthase in Cryptosporidium parvum. Mol Biochem Parasitol 105(2):253-260
175. Zhu G, LaGier MJ, Stejskal F, Millership JJ, Cai X, Keithly JS (2002) Cryptosporidium parvum: the first protist known to encode a putative polyketide synthase. Gene 298(1):79-89